GD
Elite in Urea Cycle Disorders (UCD)

Dr. George A. Diaz

Icahn School Of Medicine At Mount Sinai
New York, NY
Elite
 in Urea Cycle Disorders (UCD)
Specialties:Pediatrics | Medical Genetics
Experience:29 Years
Clinical Trials:Currently Recruiting for 5 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

View 2 More Conditions +
Check Dr. George A. Diaz's experience treating your condition:
About Dr. George A. Diaz

George Diaz is a Pediatrics specialist and a Medical Genetics expert in New York, New York. Diaz has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Urea Cycle Disorders (UCD). He is also highly rated in 17 other conditions, according to our data. His top areas of expertise are Urea Cycle Disorders (UCD), Inborn Amino Acid Metabolism Disorder, Arginase Deficiency, and Ornithine Transcarbamylase Deficiency. He is licensed to treat patients in New York. Diaz is currently accepting new patients.

His clinical research consists of co-authoring 88 peer reviewed articles and participating in 14 clinical trials in the past 15 years. In particular, he has co-authored 29 articles and participated in 10 clinical trials in the study of Urea Cycle Disorders (UCD).

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. George A. Diaz it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Locations
New York, NY 10029
Background & Education
Graduate Institution
State University Of Ny Upstate Medical University, 1994
Specialties
Pediatrics
Medical Genetics
Licenses
Pediatrics in NY
Hospital Affiliations
Mount Sinai Morningside
Mount Sinai Beth Israel
Mount Sinai Medical Center
Languages Spoken
English
Hebrew
Spanish
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials
A Phase 3 Study of PTC923 in Subjects With Phenylketonuria
Enrollment Status: Recruiting
Publish Date: November 25, 2022
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
A Phase 3 Open-Label Extension Study of PTC923 in Phenylketonuria
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Drug
Study Drug: PTC923
Study Phase: Phase 3
Longitudinal Study of Urea Cycle Disorders
Enrollment Status: Recruiting
Publish Date: April 15, 2021
Orphan Europe Carbaglu® Surveillance Protocol
Enrollment Status: Recruiting
Publish Date: August 30, 2022
A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders
Enrollment Status: Recruiting
Publish Date: April 18, 2022
Intervention Type: Drug
Study Drugs: RAVICTINaPBA
Study Phase: Phase 4
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 4
PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency
Enrollment Status: Active, not recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drug: PEG-Zilarginase
Study Phase: Phase 3
A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label Study of the Efficacy and Safety of SYNB1618 and SYNB1934 in Patients With Phenylketonuria (SynPheny-1)
Enrollment Status: Completed
Publish Date: October 17, 2022
Intervention Type: Drug
Study Drug: SYNB1618
Study Phase: Phase 2
An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A
Enrollment Status: Active, not recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drug: AEB1102
Study Phase: Phase 2
Understanding Health Insurance Literacy and Challenges in Accessing Health Services in Niemann-Pick Disease Through the Eyes of Patients and Families
Enrollment Status: Completed
Publish Date: October 06, 2020
Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders
Enrollment Status: Terminated
Publish Date: October 02, 2015
View 8 Less Clinical Trials -
88 Total Publications
One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency.
Journal: Genetics in medicine : official journal of the American College of Medical Genetics
Published: October 07, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
KO
Dr. Kimihiko Oishi
Medical Genetics | Pediatrics
Advanced
Highly rated in
5
conditions
Medical Genetics
Pediatrics

Atran Berg Laboratory Building

1428 Madison Ave, 
New York, NY 

Kimihiko Oishi is a Medical Genetics specialist and a Pediatrics expert in New York, New York. Oishi has been practicing medicine for over 29 years and is rated as an Advanced expert by MediFind in the treatment of Urea Cycle Disorders (UCD). He is also highly rated in 5 other conditions, according to our data. His top areas of expertise are Inborn Amino Acid Metabolism Disorder, Ornithine Translocase Deficiency, Ornithine Transcarbamylase Deficiency, and Urea Cycle Disorders (UCD). He is licensed to treat patients in New York.

CC
Dr. Carlos Castillo-Pinto
Neurology | Child Neurology | Pediatrics
Experienced
Highly rated in
0
conditions
Neurology
Child Neurology
Pediatrics

234 E 149th St, 
Bronx, NY 
 2.4 mi

Carlos Castillo-Pinto is a Neurologist and a Child Neurologist in Bronx, New York. Castillo-Pinto is rated as an Experienced expert by MediFind in the treatment of Urea Cycle Disorders (UCD). His top areas of expertise are Urea Cycle Disorders (UCD), Inborn Amino Acid Metabolism Disorder, Dysarthria, and Epilepsy in Children. He is licensed to treat patients in Washington.

PP
Dr. Pankaj Prasun
Pediatrics | Medical Genetics
Experienced
Highly rated in
3
conditions
Pediatrics
Medical Genetics

Mount Sinai Health System

Mount Sinai Genetics

1428 Madison Ave, 
New York, NY 

Pankaj Prasun is a Pediatrics specialist and a Medical Genetics expert in New York, New York. Prasun has been practicing medicine for over 22 years and is rated as an Advanced expert by MediFind in the treatment of Urea Cycle Disorders (UCD). He is also highly rated in 3 other conditions, according to our data. His top areas of expertise are Methylmalonic Acidemia with Homocystinuria, MELAS Syndrome, Ornithine Transcarbamylase Deficiency, and Homocystinuria. He is licensed to treat patients in Michigan. Prasun is currently accepting new patients.